Con tu permiso, usamos análisis limitados y respetuosos con la privacidad para entender qué recorridos de investigación funcionan. No usamos rastreadores publicitarios ni grabación de sesiones. Puedes cambiar esta opción en Preferencias. Lee la Política de privacidad.
Quote this valuation with its source: Fair value, Potential value and the price at analysis.
FAQ
ZBH — frequently asked questions
Is Zimmer Biomet Holdings, Inc. overvalued?
In our latest published analysis dated 2026-10-11, ZBH looks meaningfully undervalued. The price recorded at analysis is 89,1 USD versus our fair value of 120 USD; the high endpoint is presented separately as potential value of 186 USD. That implies roughly 34.2% upside to fair value at that date.
Our latest published report, analyzed 2026-10-11, gives ZBH a fair value of 120 USD and a potential value of 186 USD. The conclusion is triangulated across multiple valuation models and weighted by reliability for Zimmer Biomet Holdings, Inc.'s archetype; it is a dated research output, not a live price.
Should I buy ZBH now?
Our latest published rating for ZBH, analyzed 2026-10-11, is Strong Buy. Zimmer Biomet Holdings, Inc. looks meaningfully undervalued at the analysis-date price of 89,1 USD versus fair value of 120 USD; potential value is 186 USD. This is research for educational purposes, not personalized investment advice.
What are the biggest risks for ZBH?
The dedicated bear-case section in our report analyzed 2026-10-11 documents Zimmer Biomet Holdings, Inc.'s material risks, evidence, thresholds, and thesis-invalidation conditions. Scenario-specific explanations remain in that section so the report does not repeat or decontextualize them elsewhere.
What is ZBH's rating?
Our latest published rating for ZBH, analyzed 2026-10-11, is Strong Buy, with a published moat assessment of 7.5/10 (Narrow). It reflects our fair value of 120 USD, the potential value of 186 USD, and the price recorded at analysis (89,1 USD).
Este informe aún no se ha traducido. Actualice en unos minutos una vez que la cola de traducción se ponga al día.
§1 Resumen ejecutivoEN
Respuesta en 30 segundosStrong Buy
Precio frente a valor
Precio
$89.14
Valor razonable
$119.59
Valor potencial
$185.55
A fecha de
2026-10-09
Por qué puede funcionar
The biggest opportunity lies in accelerated hospital and ASC adoption of the ROSA surgical robotics ecosystem—where H1 2026 procedure volume matched full-year 2025 —paired with high-margin international launches like iodine-coated hips in Japan commanding ~40% price premiums.
Qué cambiaría nuestra opinión
Annual realized pricing pressure exceeding 100 basis points driven by Medicare CJR-X bundle cuts and proposed Physician Fee Schedule reductions.
Zimmer Biomet Holdings Inc. (ZBH) is assigned a Strong Buy rating with an intrinsic Fair value of $119.59, offering 34.16% upside (25.46% price discount) from the share price of $89.14 as of October 9, 2026. The market overpenalizes transitory commercial salesforce restructuring friction while ignoring entrenched surgeon switching costs in core knee reconstruction, durable ~71% gross margins, and accelerating surgical robotics utilization.4,5
At $89.14 as of October 9, 2026, Zimmer Biomet trades at 10.05x forward earnings, a wide valuation discount to medtech peers such as Boston Scientific at 12.65x and Steris at 17.51x. This compression reflects investor caution regarding a three-stage commercial salesforce reorganization scheduled through year-end 2027, which contracts FY2026 operating margins by a little more than 50 basis points alongside ongoing procedural pricing pressure of 80 to 100 basis points.
However, the underlying fundamentals of the business remain exceptionally robust. Core Product Knees generated $3,322.3M or 40.4% of FY2025 net sales ($8,231.5M). High surgeon switching costs protect this procedural base, while hospital wait times hold steady at 3 to 6 months. Furthermore, surgical robotics momentum is accelerating: procedure volumes on the ROSA platform in H1 2026 equaled full-year 2025 volume, locking in long-term consumable implant pull-through. In addition, international rollouts such as first-to-world iodine-coated hips in Japan command ~40% price premiums, helping offset domestic pricing headwinds.5,6,7
Cash conversion provides a powerful shareholder return engine. Low annual capital expenditures of $224.5M (2.7% of revenue in FY2025) relative to D&A of $1,093.8M allow the company to fund up to $1.0 billion in share repurchases in FY2026. This repurchasing power dwarfs stock-based compensation of $90.2M, reducing diluted share count by ~1.5% and driving EPS accretion from $8.53 in FY2026 to $9.07 in FY2027. Intrinsic Fair value of $119.59 represents a compelling opportunity to own a market leader at a deep cyclical discount.1,5,6
Deep Valuation Disconnect Against Medtech Peers
Trading at 10.05x forward P/E, ZBH sits at a meaningful discount to medtech peers BSX (12.65x) and STE (17.51x), creating 34.16% upside to Fair value of $119.59.3,4
Surging Surgical Robotics Adoption
H1 2026 ROSA robotic procedure cases equaled full-year 2025 volume, driving implant pull-through across knees, hips, and shoulders.5
Substantial Capital Return and Share Reduction
Planned capital return of up to $1.0 billion in share repurchases outpaces stock-based compensation of $90.2M, reducing share count and boosting EPS accretion.5,6
Recomendación de la casa
Strong Buy. Zimmer Biomet is a mispriced mature compounder trading at 10.05x forward P/E, offering a 25.46% discount and 34.16% upside to our intrinsic Fair value of $119.59. The market overweights transitory commercial salesforce restructuring costs while underappreciating durable surgeon switching costs, ~71% gross margins, and rapid ROSA robotics adoption.4,5
Descripción general de la empresa
Zimmer Biomet Holdings Inc. is a global medical technology leader specializing in musculoskeletal healthcare. The company designs, manufactures, and markets orthopedic reconstructive products, including knee and hip implants, sports medicine, biologics, foot and ankle products, trauma products, and surgical technologies. In FY2025, consolidated revenue reached $8,231.5M, led by Product Knees at $3,322.3M (40.4%), Product Hips at $2,093.5M (25.4%), and S.E.T. products at $2,150.2M (26.1%).
Geographically, the business serves healthcare providers across the Americas ($5,144.6M, 62.5% of FY2025 revenue), EMEA ($1,828.8M, 22.2%), and Asia Pacific ($1,258.1M, 15.3%). Its customer base spans hospital inpatient systems and rapidly growing ambulatory surgical centers, supported by integrated surgical technologies including the ROSA robotics suite.
§2 Caso bajistaEN
In a severe downside stress scenario combining an acceleration of pricing erosion to 150 basis points, prolonged salesforce turnover that contracts revenue growth below 1.5%, and debt refinancing at elevated pre-tax rates of 6.39% on $7.52B of total debt, operating margins would fall below 13.0%. Under these compounded pressures, intrinsic value compresses toward the lower valuation bound of $82.17.
In the bear case, persistent procedural pricing headwinds accelerate beyond 100 basis points due to Medicare CJR-X bundle reductions. Commercial salesforce restructuring causes disruption and territory friction through 2027, resulting in account defections to competitors. Constant currency revenue growth slows below management guidance ranges and operating margins remain compressed below 13.0%.
Cómo puede fallar esta tesis
Reimbursement Cuts and Pricing Headwind Acceleration
Realized pricing currently represents an 80 to 100 bps annual headwind. If Medicare CJR-X bundle cuts and proposed 2027 Physician Fee Schedule reductions accelerate net pricing erosion, operating margin would drop below 13.0%, impairing operating income.5
FV impact
-4.6%
Operating margin 3 points lower throughout
Trigger
Within 12 months
Señales de alerta temprana a vigilar
Los cinco acontecimientos que debilitarían nuestra tesis de inversión.
01
Realized Net Pricing Headwind
Pricing degradation beyond 150 bps indicates payer cuts and hospital purchasing resistance are overwhelming implant innovation, directly compressing gross margins below the 71% threshold.
Actual:80 bps headwind in Q2 2026, guided up to 100 bps annual pressure
Alerta si> 150 bps annual headwind for two consecutive quarters
02
Organic Constant Currency
§3 Foso competitivoEN
Narrow
Zimmer Biomet possesses a Narrow economic moat grounded in high procedural switching costs, specialized surgical instrumentation, and a growing installed base of ROSA surgical robotics consoles. In orthopedic reconstruction, surgeon brand loyalty is exceptionally durable because training on specific implant geometries and instrumentation kits creates significant operational switching barriers. In FY2025, Product Knees generated $3,322.3M or 40.4% of consolidated net sales of $8,231.5M, representing an entrenched franchise that competitors cannot easily displace.
The moat is further reinforced by surgical robotics integration. Robotic procedure volume on the ROSA platform in the first half of 2026 matched the entirety of FY2025 case volume. Because robotic console placements tie surgical workflows, pre-operative planning, and intra-operative navigation to Zimmer Biomet's proprietary implants, hospital systems face high friction when contemplating alternative suppliers. However, the moat is constrained to Narrow rather than Wide due to structural reimbursement headwinds: annual realized pricing faces an 80 to 100 bps drag, preventing the business from extracting unconstrained economic rents.
01High Surgeon Switching Costs and Specialized Instrumentation — Surgeons develop intense muscle memory and workflow familiarity with proprietary Zimmer Biomet instrumentation kits and surgical techniques. Orthopedic procedures require specialized trays and instrumentation, creating steep switching costs that protect the knee reconstruction revenue base of $3,322.3M (40.4% of FY2025 net sales).Wide
02Surgical Robotics Installed Base and Ecosystem Integration — Placement of the ROSA surgical robotics platform, ROSA Shoulder, ROSA OptimiZe, and handheld devices integrates proprietary software, pre-operative planning, and implant geometry into the hospital operating room. H1 2026 robotic procedure cases equaled the entirety of FY2025, locking in consumable implant pull-through.Moderate
Amenazas conocidas al foso
Amenaza
Severidad
Cronograma
Mitigación
Reimbursement Policy Cuts and Procedural Bundle Compression
medium
12 to 24 months
Offsetting pricing headwinds via premium innovative offerings (iodine-coated implants with 40% premium), robotic workflow efficiency, and migration into ambulatory surgical centers.5
The highlighted cell is Fair value when every assumption sits at its base level ($119.59). Each row and column shows what Fair value becomes when one assumption moves.
Free cash flow to the firm stays positive in the first projected year at $778.9M after modeled reinvestment of $137.5M, with terminal value at 83.1% of enterprise value. A sudden drop in free cash flow is not projected unless capital spending relative to revenue, reinvestment, or gross margin resets materially.
Terminal exit multiple in line with historical valuation levels
Under the base case, Zimmer Biomet executes its commercial reorganization across three stages through 2027, stabilizing domestic knee and hip market share while ROSA robotics placements expand procedural volume. FY2026 reported revenue grows 4.43% to $8,596.2M, and FY2027 revenue reaches $8,904.5M. Operating margins trough at 13.0% in FY2026 before expanding to 14.0% in FY2027 and 16.0% by FY2030. Diluted EPS expands from $8.53 in FY2026 to $9.07 in FY2027, supported by share repurchases of up to $1.0B.1,5
Revenue and earnings exceeding the high end of management guidance confirm that commercial restructuring is accelerating surgical robotic share gains without representative disruption.
En línea
Maintain Strong Buy; Maintain position weighting and monitor salesforce turnover metrics alongside gross margin stability.
A breach below guidance floors indicates commercial disruption or accelerating pricing headwinds beyond the 100 bps threshold, impairing near-term earnings power.
Calidad de los beneficios
Earnings quality is supported by stable GAAP gross margins near 71% and strong cash generation. In FY2025, operating cash flow stood well above net income of $705.1M, driven by non-cash depreciation and amortization of $1,093.8M. For the six months ended June 30, 2026, operating cash flow reached $807.2M against depreciation of $540.8M. Stock-based compensation of $90.2M in FY2025 represents a low 1.1% of revenue, well below medtech industry averages (2.1%), indicating minimal non-cash compensation dilution.5,6
Evolución de las estimaciones
Consensus revisions remained flat immediately following the Q2 2026 earnings release, reflecting management's measured guidance philosophy to 'say less and do more'. FY2026 consensus EPS remained unchanged at $8.47 immediately post-event, and FY2027 consensus EPS held at $9.00. Subsequent consensus snapshots have drifted modestly upward to $8.53 for FY2026 and $9.07 for FY2027, aligned with the raised guidance range of $8.47 to $8.59.1,5
Historical GAAP ROIC has been weighed down by the large intangible asset base from the Biomet merger and transitory restructuring charges. However, as the three-stage commercial salesforce reorganization concludes by the end of FY2027, operating margins are projected to expand from 13.0% in FY2026 to 16.0% in FY2030, driving operating profit and economic value added above capital costs.
Third-party models estimate current ROIC at 5.49% as of 2026-10-11, which temporarily sits below the moderate cost of equity of 8.0816% and WACC of 7.3575%, but cash return on invested capital expands as commercial reorganization completes.
Commercial Restructuring Depresses FY2026 Margins Before Unlocking Leverage
Management guidance anticipates contraction of a little more than 50 basis points in FY2026 due to dedicated salesforce investments and Paragon 28 .
Ingresos más recientes8231,5 M US$CAGR de ingresos +0,8 %
Margen operativo13,3 %10 periodos fiscales
Flujo de caja libre más reciente1472,6 M US$FY2025
Deuda neta6927,2 M US$FY2025
Desglose de la cuenta de resultadosCómo la escala del negocio se convierte en beneficio declarado.
StockMarketAgent.AI
Ingresos8231,5 M US$Coste de ventas−3159,6 M US$Beneficio bruto5071,9 M US$Gastos operativos−3973,8 M US$Beneficio operativo1098,1 M US$Partidas no operativas e impuestos−393 M US$Beneficio neto705,1 M US$
Datos del historial financiero
Ingresos
8.231.500.000 US$
Coste de ventas
3.159.600.000 US$
Beneficio bruto
5.071.900.000 US$
Gastos operativos
3.973.800.000 US$
Beneficio operativo
1.098.100.000 US$
Partidas no operativas e impuestos
-393.000.000 US$
Beneficio neto
705.100.000 US$
Resumen del balanceCómo se mantienen y financian los activos declarados en el período seleccionado.
StockMarketAgent.AI
Composición de activosFinanciado por
Activos totales23,1 mil M US$Efectivo591,9 M US$Activos corrientes5119,9 M US$Pasivos totales10,4 mil M US$Pasivos corrientes2583,7 M US$Patrimonio neto12,7 mil M US$
Datos del desglose del balance
Activos totales
23.091.700.000 US$
Efectivo
591.900.000 US$
Activos corrientes
5.119.900.000 US$
Pasivos totales
10.386.000.000 US$
Pasivos corrientes
2.583.700.000 US$
Patrimonio neto
12.705.800.000 US$
Puente de flujo de cajaCómo el flujo de caja operativo se convirtió en flujo de caja libre en FY2025.
StockMarketAgent.AI
Conciliación del flujo operativo
Beneficio neto705,1 M US$Depreciación y amortización+1093,8 M US$Compensación basada en acciones+90,2 M US$Otros ajustes operativos−192 M US$Flujo de caja operativo1697,1 M US$
Conciliación del efectivo inicial al final
Efectivo inicial525,5 M US$Flujo de caja operativo+1697,1 M US$Flujo de inversión−1975,7 M US$Flujo de financiación+326 M US$Efecto del tipo de cambio+19 M US$Efectivo final591,9 M US$
1697,1 M US$ − 224,5 M US$Flujo de caja libre 1472,6 M US$
Datos del puente de flujo de caja
Beneficio neto
705.100.000 US$
Entrada operativa
1.889.100.000 US$
Depreciación y amortización
1.093.800.000 US$
Compensación basada en acciones
90.200.000 US$
Flujo de caja operativo
1.697.100.000 US$
Salida operativa
192.000.000 US$
Efectivo disponible
2.567.600.000 US$
Efectivo inicial
525.500.000 US$
Entrada de financiación
326.000.000 US$
Efecto del tipo de cambio
19.000.000 US$
Salida de inversión
1.975.700.000 US$
Capex
224.500.000 US$
Otras actividades de inversión
1.751.200.000 US$
Efectivo final
591.900.000 US$
Flujo de inversión
-1.975.700.000 US$
Flujo de financiación
326.000.000 US$
Ingresos por categoría de negocioProporción de los ingresos totales de 2025-12-31.
8231,5 M US$Ingresos totales
Ingresos por categoría de negocioProporción
Knees3322,3 M US$40,4 %+4,7 % interanual
SET2150,2 M US$26,1 %+15,2 % interanual
Hips2093,5 M US$25,4 %+4,7 % interanual
Technology And Data Bone Cement And Surgical665,6 M US$8,1 %+4 % interanual
Fuente: SEC EDGAR · Presentado 2026-02-20 · SEC EDGAR
Datos de composición de ingresos: Ingresos por categoría de negocio
Ingresos por categoría de negocio
Ingresos
Proporción
interanual
Knees
3322,3 M US$
40,4 %
4,7 %
SET
2150,2 M US$
26,1 %
15,2 %
Hips
2093,5 M US$
25,4 %
4,7 %
Technology And Data Bone Cement And Surgical
665,6 M US$
8,1 %
4 %
Ingresos por regiónProporción de los ingresos totales de 2025-12-31.
8231,5 M US$Ingresos totales
Ingresos por regiónProporción
Americas5144,6 M US$62,5 %+7,3 % interanual
EMEA1828,8 M US$22,2 %+8,1 % interanual
Asia Pacific1258,1 M US$15,3 %+5,5 % interanual
Fuente: SEC EDGAR · Presentado 2026-02-20 · SEC EDGAR
Datos de composición de ingresos: Ingresos por región
Ingresos por región
Ingresos
Proporción
interanual
Americas
5144,6 M US$
62,5 %
7,3 %
EMEA
1828,8 M US$
22,2 %
8,1 %
Asia Pacific
1258,1 M US$
15,3 %
5,5 %
Ingresos y beneficiosCómo la escala del negocio se convierte en beneficio declarado.
Efectivo y deudaLiquidez disponible frente al endeudamiento total.
Generación de efectivoFlujo de caja operativo frente al flujo de caja libre.
RentabilidadEvolución de los márgenes bruto, operativo y neto.
Datos financieros puntuales utilizados en el análisis del 2026-10-11.
Datos del historial financiero
Período
Ingresos
EBITDA
Beneficio neto
Flujo de caja operativo
Flujo de caja libre
Capex
Depreciación y amortización
Compensación basada en acciones
Recompras de acciones
Dividendos pagados
Emisión neta de deuda
Flujo de inversión
Flujo de financiación
Efectivo inicial
Efectivo final
Efectivo e inversiones
Deuda total
Margen operativo
ROIC
WACC
Diferencial ROIC−WACC
2016-12-31
7668,4 M US$
1793,9 M US$
305,9 M US$
1632,2 M US$
1447,5 M US$
184,7 M US$
1039,3 M US$
57,3 M US$
415,5 M US$
188,4 M US$
—
-1691,5 M US$
-743,2 M US$
—
634,1 M US$
634,1 M US$
11,2 mil M US$
10,7 %
—
5,5 %
—
2017-12-31
7803,3 M US$
1852,6 M US$
1813,8 M US$
1582,3 M US$
1426,3 M US$
156 M US$
1062,7 M US$
53,7 M US$
—
193,6 M US$
—
-510,8 M US$
-1210,5 M US$
634,1 M US$
524,4 M US$
524,4 M US$
10,1 mil M US$
10,2 %
—
5,6 %
—
2018-12-31
7932,9 M US$
1058,7 M US$
-379,2 M US$
1747,4 M US$
1584,7 M US$
162,7 M US$
1040,5 M US$
65,5 M US$
—
195,2 M US$
—
-416,6 M US$
-1302,2 M US$
524,4 M US$
542,8 M US$
542,8 M US$
8938,7 M US$
0,4 %
—
9,4 %
—
2019-12-31
7982,2 M US$
2138,8 M US$
1131,6 M US$
1585,8 M US$
1378,7 M US$
207,1 M US$
1006,1 M US$
84,3 M US$
—
196,7 M US$
—
-729,3 M US$
-779,9 M US$
542,8 M US$
617,9 M US$
617,9 M US$
8221,4 M US$
14,3 %
—
5,4 %
—
2020-12-31
6127,5 M US$
1005,3 M US$
-138,9 M US$
1204,5 M US$
1092,6 M US$
111,9 M US$
898,4 M US$
73,8 M US$
—
198,5 M US$
—
-613,8 M US$
-421,8 M US$
617,9 M US$
802,1 M US$
802,1 M US$
1000 M US$
1,4 %
—
6,2 %
—
2021-12-31
6827,3 M US$
1645,1 M US$
401,6 M US$
1499,2 M US$
1355,6 M US$
143,6 M US$
937,7 M US$
76 M US$
—
200,1 M US$
—
-503,6 M US$
-1306 M US$
802,1 M US$
378,1 M US$
394,4 M US$
1000 M US$
12,6 %
—
6,3 %
—
2022-12-31
6939,9 M US$
1494,7 M US$
231,4 M US$
1284,7 M US$
1096,8 M US$
187,9 M US$
926,4 M US$
105 M US$
126,4 M US$
201,2 M US$
-1060,7 M US$
-529,2 M US$
-843,8 M US$
478,5 M US$
375,7 M US$
382,5 M US$
5696,5 M US$
10,0 %
—
7,6 %
—
2023-12-31
7394,2 M US$
2220,2 M US$
1024 M US$
1581,6 M US$
1290,5 M US$
291,1 M US$
951,7 M US$
99,8 M US$
692,2 M US$
200,9 M US$
54,6 M US$
-778,9 M US$
-763,5 M US$
375,7 M US$
415,8 M US$
442 M US$
5767,9 M US$
17,3 %
—
7,6 %
—
2024-12-31
7678,6 M US$
2250,9 M US$
903,8 M US$
1499,4 M US$
1295,6 M US$
203,8 M US$
996,3 M US$
101 M US$
868 M US$
196 M US$
536,3 M US$
-888,1 M US$
-484,5 M US$
415,8 M US$
525,5 M US$
525,5 M US$
6204,6 M US$
16,7 %
—
8,0 %
—
2025-12-31
8231,5 M US$
2217,4 M US$
705,1 M US$
1697,1 M US$
1472,6 M US$
224,5 M US$
1093,8 M US$
90,2 M US$
487 M US$
190,3 M US$
1029,1 M US$
-1975,7 M US$
326 M US$
525,5 M US$
591,9 M US$
591,9 M US$
7519,1 M US$
13,3 %
—
6,0 %
—
§9 Comparación de valoración con pares
Valor razonableReport-date price
Zimmer Biomet Holdings, Inc.ZBH
Precio / valor razonable
Valor razonable119,59 US$Report-date price89,14 US$
Fecha de evaluación
Ventaja competitivaNarrow
Cuadro de mando de inversión67 / 100
STERIS plcSTE
Precio / valor razonable
Valor razonable209,55 US$Report-date price214,4 US$
Fecha de evaluación
Ventaja competitivaWide
Cuadro de mando de inversión69 / 100
GE HealthCare Technologies Inc.GEHC
Precio / valor razonable
Valor razonable68,29 US$Report-date price64,29 US$
Fecha de evaluación
Ventaja competitivaNarrow
Cuadro de mando de inversión62 / 100
Zimmer Biomet Holdings, Inc.ZBH
Precio / valor razonable
Valor razonable119,59 US$Report-date price89,14 US$
Zimmer Biomet Holdings Inc. (ZBH) trades at 10.1x forward earnings against a peer median of 15.1x. Its EV/EBITDA of 9.5x compares with a peer median of 13.2x. The comparison uses 4 peers: STERIS plc, GE HealthCare Technologies Inc., DexCom Inc. and Boston Scientific Corporation, as of 2026-10-11.
§10 Industria y cicloEN
Fase del ciclo
Contraction
Medical device industry benchmarks show capex-to-revenue of 4.5% and capex-to-depreciation of 0.8x as of 2026-10-05, compared to Zimmer Biomet's FY2025 capex of $224.5M (2.7% of $8,231.5M revenue). Because specific data on industrial capacity utilization, order backlogs, component lead times, and customer concentration are unavailable, the industry cycle assessment is demand-led and evidence-limited.6
Ciclo alcista
In a bull cycle scenario, surgical backlogs clear rapidly as hospital staffing normalizes, wait times contract from 3 to 6 months, ambulatory surgical center migration accelerates procedure volume, and international demand for premium technologies such as iodine-coated hips in Japan (commanding 40% premiums) expands procedural volumes above 5% annually.
Ciclo bajista
In a bear cycle scenario, persistent healthcare system margin pressure and regulatory reimbursement cuts (such as Medicare CJR-X bundle reductions) exacerbate procedural pricing headwinds beyond 100 bps, while hospital capital spending constraints slow robotic console acquisitions.
Tendencias seculares
Tendencia
Impacto
Nota
Aging Global Demographics and Joint Wear
positive
An expanding population aged 65 and older drives steady secular growth in total knee and hip arthroplasty procedures, supported by long hospital waiting lists of 3 to 6 months.
Shift to Ambulatory Surgical Centers (ASCs)
positive
Surgeons increasingly perform outpatient joint reconstructions in ASCs, where implants represent 14% to 15% of total procedure costs, creating strong demand for compact surgical robotics like ROSA OptimiZe and handheld tools.
Posicionamiento
Zimmer Biomet is strongly positioned within the orthopedic cycle as the co-market leader in large joints, generating $3,322.3M in Knees (40.4% of FY2025 revenue) and $2,093.5M in Hips (25.4%). Its comprehensive technology suite—spanning ROSA robotics, ROSA Shoulder, and mixed-reality navigation —positions the company to capture outpatient ASC market share while maintaining gross margins around 71%.5,7
§11 Gestión de posiciónEN
Tamaño de posición
4-6%
A 4-6% portfolio allocation reflects high conviction in the durable clinical switching costs protecting the core knee franchise ($3,322.3M or 40.4% of FY2025 revenue), ~71% gross margins, and a depressed valuation multiple of 10.05x forward P/E that offers substantial margin of safety to fair value of $119.59.4,5,7
Riesgo
Risk management centers on monitoring commercial reorganization milestones and reimbursement shifts. The position size is capped at 6.0% of portfolio equity to manage exposure to medtech regulatory and policy changes. Downside risk is managed through quarterly fundamental audits of surgeon retention and gross margin thresholds rather than mechanical price stop-outs, preserving exposure to the company's substantial free cash flow yield and up to $1.0 billion capital return program.
Tramos de entrada
Nivel
Acción
Por qué
$88.00 - $90.00
Initiate 60% of target position
The share price of $89.14 as of October 9, 2026 offers an attractive 25.46% discount to fair value of $119.59 and a 10.05x forward P/E.
$82.00 - $85.00
Deploy remaining 40% of target position
Tramos de salida
Nivel
Acción
$118.00 - $120.00
Trim 30% of position upon convergence with house Fair value ($119.59)
$140.00 - $150.00
Trim an additional 30% as valuation expands toward historical median medtech peer multiples
$180.00+
Harvest remaining position as shares approach the bull case ($185.55)
Zimmer Biomet trades at an undemanding forward P/E of 10.05x, representing a significant discount to peers BSX (12.65x) and STE (17.51x). At $89.14, the stock offers a 25.46% discount to its Fair value of $119.59, underpinned by stable ~71% gross margins and up to $1.0B in share repurchases.3,4,5
Growth & Quality Investor
Buy
Adoption of the ROSA surgical robotics platform is accelerating, with H1 2026 case volumes matching all of FY2025. First-to-world products like iodine-coated hips command 40% premiums in Japan, positioning the company for accelerating EPS growth toward $9.07 in FY2027 as commercial restructuring finishes.1,5
Bear Case Skeptic
Hold
Downside risks center on persistent 80 to 100 bps annual pricing erosion compounded by potential surgeon disruption during the three-stage commercial salesforce reorganization extending through 2027. If representative turnover leads to defections of high-volume orthopedic surgical accounts to rivals, organic revenue growth would fail to reach the guided 2.25%-3.25% range, capping operating margin recovery.5
§14 Recomendación finalEN
Acción
Compra fuerte
Zimmer Biomet represents a high-conviction Strong Buy with an intrinsic Fair value of $119.59, offering 34.16% upside from the share price of $89.14 as of October 9, 2026. The company's deep clinical moat in large joint reconstruction, sticky surgeon switching costs, and ~71% gross margins protect cash flows while commercial restructuring noise creates an exceptional valuation discount at 10.05x forward P/E.4,5
With up to $1.0 billion in capital return via share repurchases and rapid uptake of ROSA surgical robotics, investors are well-compensated through substantial fundamental cash flow accretion as temporary salesforce transition costs subside by 2027.
§15Your notes
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Private notes
Visible only to you. Synced to this device.
0 chars
Sources
The records this analysis drew on, as they stood when it was run.
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
Commercial Salesforce Disruption and Orthopedic Account Defection
Management's commercial reorganization spans three stages through the end of 2027. If representative turnover leads to surgeon disruption and competitive account losses to Stryker or J&J, constant currency revenue growth would fall below 1.5% YoY compared to management's organic guidance of 2.25%-3.25%.5
FV impact
-6.5%
Revenue and EPS growth 5 points lower for five years
ZBH currently trades at 10.05x forward P/E, a discount to peer BSX at 12.65x and STE at 17.51x. If restructuring stumbles persist, the exit multiple compresses to 10.0x-10.5x rather than expanding to the modeled 13.5x.3,4
FV impact
-5.1%
Terminal multiple 20% lower
Trigger
Within 24 months
Refinancing Cost Surge and Macro Capital Cost Escalation
ZBH carries $7.52B in total debt, requiring sustained cash conversion and working capital discipline to service leverage. An increase in WACC by 100 bps from 7.3575% to 8.36% driven by debt refinancing at pre-tax rates of 6.39% depresses enterprise fair value.2,4
Growth falling below 1.5% signals that the commercial salesforce restructuring is causing territory disruption and defection of key orthopedic surgeon accounts to competitors.
Negative APAC growth would prove that China volume-based procurement pressure and tender delays are neutralizing the premium pricing gains achieved in Japan.
Alerta si<= 0.0% constant currency growth for two consecutive quarters
05
Total Debt Cost and Capital Burden
Escalating debt refinancing costs and higher cost of capital depress enterprise fair value and restrict capital return capacity.
Actual:$7,519.1M total debt in FY2025
Alerta siWACC exceeding 8.36% or borrowing rate above 6.39%
03
Proprietary Intangible Assets and Differentiated Surface Technologies — Patented material science innovations such as Trabecular Metal and first-to-world iodine-coated hip implants in Japan command ~40% price premiums by addressing periprosthetic joint infection risks, supported by extensive clinical registry data and regulatory clearances.
Moderate
Salesforce Turnover During Commercial Reorganization
medium
Through end of FY2027
Three-stage phased implementation transitioning to specialized dedicated sales structures without aggressive headcount disruptions.5
Emerging Market Centralized Procurement Tenders
low
Ongoing
Geographic diversification across EMEA ($1,828.8M) and APAC ($1,258.1M), and premium technology adoption in mature markets like Japan.7
Discounted forecast-period cash flows (19,79 US$) plus discounted terminal value (96,99 US$) minus signed per current share (36,32 US$) equals the 80,46 US$ lens value shown above. Negative net debt is , so subtracting it raises value.
In the bull case, rapid ROSA surgical robotics placement drives accelerating market share gains in knees and shoulders, while international launches of first-to-world iodine-coated hips in Japan achieve rapid market conversion at 40% premiums. Salesforce specialization concludes ahead of schedule with negligible turnover. Revenue growth accelerates to 5.0% and operating margins reach 17.0%, propelling intrinsic value toward $185.55.5
Management pursues a balanced capital allocation strategy prioritizing tuck-in M&A and share repurchases. Capital returns in FY2026 target up to $1.0 billion in share repurchases, which comfortably exceeds annual stock-based compensation of $90.2M. Total debt stands at $7,519.1M as of year-end FY2025 ($7,601.7M total debt input in cost of capital), with long-term debt of $6,932.0M reported as of June 30, 2026. Management has maintained a disciplined acquisition envelope of up to $2.0 billion for targets that are revenue-accretive, EPS-accretive by year two, and exceed double-digit ROIC by year five.
FY2026 represents the trough operating margin (13.0%), providing an attractive entry point before margins expand toward 14.0% in FY2027 and 16.0% by FY2030.
Planned capital returns include up to $1.0 billion in share repurchases in FY2026, which dwarfs annual stock-based compensation of $90.2M.
Diluted share count contracts by 1.5% in FY2026 from 198.7M shares in FY2025, boosting compound EPS growth to 6.2% in FY2027.
DexCom, Inc.DXCM
Precio / valor razonable
Valor razonable58,97 US$Report-date price85,36 US$
Fecha de evaluación
Ventaja competitivaWide
Cuadro de mando de inversión67 / 100
Boston Scientific CorporationBSX
Precio / valor razonable
Valor razonable65,94 US$Report-date price44,51 US$
Fecha de evaluación
Ventaja competitivaNarrow
Cuadro de mando de inversión72 / 100
Margen
ZBH
Zimmer Biomet Holdings Inc.
$17.0B
10.1x
2.0x
9.5x
6.4%
—
STE
STERIS plc
$20.9B
17.5x
3.5x
13.5x
11.4%
19.2%
GEHC
GE HealthCare Technologies Inc.
$29.9B
12.2x
1.4x
10.5x
19.4%
15.0%
DXCM
DexCom Inc.
$31.7B
26.9x
6.4x
22.3x
38.5%
24.3%
BSX
Boston Scientific Corporation
$61.9B
12.6x
2.9x
12.8x
15.3%
22.9%
Healthcare Payer Reimbursement Compression
negative
Government programs like Medicare CJR-X and bundled payments create persistent 80 to 100 bps annual pricing headwinds, requiring implant manufacturers to offer differentiated technology to defend realization.
Add aggressively if market volatility drives shares toward the conservative cash flow floor, providing exceptional asymmetric upside.
Re-evaluate commercial restructuring costs and reduce terminal operating margin assumptions.5
ROSA Robotics Procedure Volume
Deceleration below 15% year-over-year growth
Assess hospital capex constraints and evaluate competitive robotic placements from rival systems.5
The biggest opportunity lies in accelerated hospital and ASC adoption of the ROSA surgical robotics ecosystem—where H1 2026 procedure volume matched full-year 2025 —paired with high-margin international launches like iodine-coated hips in Japan commanding ~40% price premiums. This combination drives market share gains in knees and shoulders, lifting operating margins toward 16.0% and propelling intrinsic value toward the bull case of $185.55.
